Kanako Kato

Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Masanori Shimizu, Kunihiro Suzuki, Kanako Kato et al. · Diabetes Obesity and Metabolism · 2018 · 378 citations

Medicine, Pharmacology, Pharmacotherapy +17

Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging

Chigumi Ohtsuka, Makoto Sasaki, Kanako Konno et al. · Neuroscience Letters · 2013 · 175 citations

Medicine, Neurology, Neuroscience +17

Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging

Chigumi Ohtsuka, Makoto Sasaki, Kanako Konno et al. · Parkinsonism & Related Disorders · 2014 · 158 citations

Medicine, Neurology, Neuroscience +14

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase‐4 in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Yoshimasa Aso, Kanako Kato, Shintaro Sakurai et al. · International Journal of Clinical Practice · 2019 · 97 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Impaired metabolism of kynurenine and its metabolites in CSF of parkinson’s disease

Kazuhiro Iwaoka, Chigumi Otsuka, Tetsuya Maeda et al. · Neuroscience Letters · 2019 · 52 citations · Full text

Life Sciences, Neuroscience, Pharmacology +10